Molecular profiling of DNA and RNA has provided valuable new insights into the genetic basis of non-malignant and malignant disorders as well as an increased understanding of basic mechanisms that regulate human disease.
These advances have important implications for future research and clinical practice in areas as molecular diagnostics, the implementation of gene or pathway-directed targeted therapy, and the use of such information to drive drug discovery.
It is well known that both inherited and somatic genetic alterations contribute to predisposition, transformation, disease progression, responsiveness to therapy, and treatment complications. Recent technological advances have enabled the analyses of genomic and epigenomic variation in a comprehensive, high-throughput fashion using next generation sequencing.
These approaches have transformed the understanding of malignancies in recent years, with important implications for clinical care of different disease including cancer. Next generation sequencing has shown that each tumor type typically exhibits distinct constellations of genetic alterations that target one or more key cellular pathways that regulate cell growth and proliferation, evasion of the immune system, and other aspects of cancer behavior. Genetic and epigenetic events have been identified and may be used as prognostic markers or for monitoring disease and treatment response: germline/inherited mutations for use in genetic counseling and disease surveillance, pathways and genes that may serve as targets for new therapies.
The conference wants to offer the opportunity to match technological solutions and clinical needs in the era of precision medicine. From circulating biomarkers, to mutational, transcriptomics and immunomics landscape, the meeting will describe a panorama of the renewed platforms for personalization of therapy.